CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
18 hedge funds and large institutions have $1.98M invested in CASI Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 4 closing their positions.
124% more capital invested
Capital invested by funds: $883K → $1.98M (+$1.1M)
89% more call options, than puts
Call options by funds: $17K | Put options by funds: $9K
0.52% less ownership
Funds ownership: 2.59% → 2.07% (-0.52%)
5% less funds holding
Funds holding: 19 → 18 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$62.1K |
| 2 |
Renaissance Technologies
New York
|
+$54.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.88K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$255 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSC
Wellington Shields & Co
New York
|
-$149K |
| 2 |
WSCM
Wellington Shields Capital Management
New York
|
-$97.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$82.9K |
| 4 |
Jane Street
New York
|
-$46.1K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$840 |
CASI Hedge Fund Activity: Q4 2023 in Review
18 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q4 2023, worth a combined $1.98M — up 124% from $883K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CASI and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $62.1K. The largest seller was Wellington Shields & Co, cutting an estimated $149K.
- 18 institutional investors held CASI Pharmaceuticals (CASI) as of Q4 2023, down from 19 in Q3 2023.
- Funds reported $1.98M of CASI Pharmaceuticals stock for Q4 2023, up 124% quarter-over-quarter.
- 3 funds opened new CASI Pharmaceuticals positions in Q4 2023 and 4 closed out, a net change of -1 holder.
- The largest CASI Pharmaceuticals buyer in Q4 2023 was Citadel Advisors, an estimated $62.1K added.
- The largest CASI Pharmaceuticals seller in Q4 2023 was Wellington Shields & Co, an estimated $149K sold.
Based on aggregated 13F filings for Q4 2023.